Literature DB >> 25632477

Development and validation of a high-performance liquid chromatographic method for the simultaneous quantification of marker constituents in Cheonwangbosimdan.

Chang-Seob Seo, Hyeun-Kyoo Shin.   

Abstract

A high-performance liquid chromatography-photodiode array detector method was established for the simultaneous determination of 7 components in Cheonwangbosimdan extract. The components were 5-hydroxymethyl-2-furaldehyde (1), coptisine (2), berberine (3), nodakenin (4), harpagoside (5), cinnamic acid (6), and β-asarone (7). All analytes were separated by gradient elution using two mobile phases on a Gemini C18 column and maintained at 40°C. The flow rate was 1.0 mL/min and the injection volume was 10 μL. Calibration curves of the 7 compounds showed good linearity with correlation coefficients (r2) ≥ 0.9996. The limits of detection and quantification of the 7 analytes were 0.01-0.04 and 0.03-0.12 μg/mL, respectively. The recoveries of the 7 marker constituents were 97.6-104.2% with relative standard deviations (RSD) of less than 2.2%. The RSD values of intra- and interday precision were 0.11-1.78 and 0.19-1.92%, respectively. Among the 7 biomarker compounds, the major compounds of Cheonwangbosimdan were berberine and coptisine, which originated from Coptisjaponica. The results indicate that the developed analytical method is suitable for quality control use.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25632477

Source DB:  PubMed          Journal:  Nat Prod Commun        ISSN: 1555-9475            Impact factor:   0.986


  2 in total

1.  Anti-microbial and anti-inflammatory effects of Cheonwangbosim-dan against Helicobacter pylori-induced gastritis.

Authors:  Hee Seon Park; Hye Yun Jeong; Young Suk Kim; Chang Seob Seo; Hyekyung Ha; Hyo Jung Kwon
Journal:  J Vet Sci       Date:  2020-05       Impact factor: 1.672

2.  Vasorelaxant and Hypotensive Effects of Cheonwangbosimdan in SD and SHR Rats.

Authors:  Bumjung Kim; Cheolmin Jo; Ho-Young Choi; Kyungjin Lee
Journal:  Evid Based Complement Alternat Med       Date:  2018-07-10       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.